Roger G. Worthington P.C.   |   800.831.9399  |  Search  
   
Helping Asbestos Victims Get Justice in the Courtrooms and Help in the Hospitals since 1990.

Expand All | Contract All Empower Yourself: Free Medical/Legal Guide

-PATIENT PROFILES -California State Rock -Empower Yourself -PHLBI -Mesothelioma -Meso Causation -Meso Diagnosis -Treatment Options -Treatment Centers -Litigation -Settlements/Verdicts -Patient Advocacy -Asbestos Products -Legislative Updates -Meso Hotspots -Lung Cancer -Why You Need RGWPC -Web Links
 
 

Listen to Dr. Cameron speak about his surgery plus interferon trial
Click here

 

Free Legal and Medical Packet

Click Here
1- 800-831-9399

 

THE REAL DEAL

Meso lawyers since 1996.
First on the Internet.
First to post treatment options.

BEWARE OF FAKES

 
 

 

MARF Letter
 

 
Board of Directors

Robert B. Cameron, M.D.
UCLA Medical School

Nicholas J. Vogelzang, M.D.
University of Chicago

M. Ann Abbe
Arlington, Texas

Michael Harbut, M.D., M.P.H.
Royal Oak, MI

Roger G. Worthington, Esq.
Dallas, Texas

Matthew Bergman, Esq.
Seattle, Washington

Susan Vento
St. Paul, Minnesota

Mouzetta Zumwalt-Weathers
Cary, North Carolina

Ulf Jungnelius M.D.
Pfizer, Inc.

In Memoriam
Congressman Bruce F. Vento

Science Advisory Board

Harvey Pass, M.D., Chairman
Karmanos Cancer Institute

Victor Roggli, M.D.
Duke University

Robert N. Taub, M.D.
Columbia University

Lary A. Robinson, M.D.
H. Lee Moffit Cancer Center

Steve Hahn, M.D.
University of Pennsylvania

Joseph R. Testa, Ph. D.
Fox Chase Cancer Center

Claire Verschraegen, M.D.
University of New Mexico

Eric Vallieres, M.D.
Swedish Cancer Institute

Dan Miller, M.D.
Emory University

Raphael Bueno, M.D.
Harvard/Brigham and Women's

Hedy Lee Kindler, M.D.
University of Chicago

W. Roy Smythe, M.D.
Texas A&M

Executive Director
Christopher E. Hahn

MARF, inc.
1609 Garden Street
Santa Barbara, CA 93101
tel (805) 560-8942
fax (805) 560-8962
c-hahn@marf.org
http://www.marf.org

MarfPlainLogo.gif (9369 bytes)

Our mission is to eradicate mesothelioma as a life-ending disease.

December 7, 2004

Dr. David N. Tornberg
Assistant
Secretary of Defense
Clinical Program Policy
1200 Defense Pentagon
Washington, DC 20301-1200

Re:

 

CDMRP for Navy Veterans Stricken with Service-Connected Malignant Mesothelioma

Dear Dr. Tornberg:

Mesothelioma is an asbestos-related cancer that exacts a heavy toll on Navy veterans.  Of the 4,000 Americans diagnosed with mesothelioma every year, approximately 32% were exposed to asbestos while serving in the U.S. Navy or while working in naval shipyards.  Despite the heavy toll this insidious cancer exacts on Navy servicemen, neither the Department of Defense nor the Department of Veterans Affairs has a medical research and treatment program for mesothelioma.  Unfortunately, the National Cancer Institute continues to grossly under fund mesothelioma research when compared to other cancers.

We are asking for your cooperation in our mission to persuade Congress to create a Congressionally Directed Medical Research Program for Mesothelioma. Congress has created CDMRPs for ovarian, prostate, breast and other cancers which are not necessarily service-connected.  From 1992 to 2005, Congress has appropriated over $3.4 billion dollars to the DOD for specific research priorities.  The time is long overdue for Congress to recognize the service and sacrifice of the thousands of veterans who either currently suffer from an asbestos-related cancer or are at a substantial risk for contracting same in the future.

The Mesothelioma Applied Research Foundation (MARF) has united patients, doctors, lawyers and former asbestos manufacturers in the mission to eradicate this terrible disease.  We have proposed the creation of a $140 million Mesothelioma Research and Treatment Program, which would fund 10 centers of excellence, establish the Admiral Elmo Zumwalt Registry and the Congressman Bruce Vento Tissue Bank.  The program MARF proposed was included in the Ban Asbestos Act (SB 1125), a bill which is pending.  There is widespread agreement that the merits of a medical research program for asbestos cancer should be considered separately from the rancorous debate over the need for asbestos civil litigation tort reform.

We would like to discuss our proposal with you.  We envision a united front that includes the DVA and the DOD, along with distinguished members of the scientific, medical, business and legal communities.  The creation of a federal program for mesothelioma research should not be tied to the success or failure of asbestos compensation reform legislation.  With your support, we can attract support from both sides of the aisle, as mesothelioma does not respect party, rank, or title. 

For your review, we are attaching a number of memoranda, letters and articles which speak to MARF's history, purpose and our impact within the medical and legal communities.  The attachments include a roadmap for curing mesothelioma, a draft of the proposed $140 million research and treatment program, a summary of the grants funded by MARF, an overview of MARF's peer-review funding mechanism, an article that discusses the options for marshalling the resources to fund medical research, and a statement by a Navy veteran afflicted with mesothelioma.

We will be calling you in the next few days to discuss this letter and the next step.  We look forward to collaborating with you and your staff.

Sincerely,

Roger G. Worthington
Founding Director

Enclosures

*** POSTED DECEMBER 13, 2004 ***

 
site map   free brochure   disclaimer   800.831.9399   contact us   home